– SWITZERLAND, Basel – The Novartis Board of Directors announced today, that it is nominating Ms. Elizabeth Doherty and Mr. Ton Büchner for election to the Board at the Annual General Meeting (AGM) of Shareholders to be held on February 23, 2016.
Ms. Doherty is a finance professional with a career spanning more than 35 years in the fast moving consumer goods industry where she developed strategies and programs to improve business outcomes and drive shareholder value. Ms. Doherty is a British national and seasoned professional having served as a CFO and member of the Board of Directors on numerous corporations.
Mr. Büchner is the CEO and Chairman of the Executive Board of AkzoNobel, a Dutch multinational active in the fields of decorative paints, performance coatings and specialty chemicals. As a business leader and engineer by training, Mr. Buechner has successfully led global companies with portfolios targeting both business to business and direct to consumer activities.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 120,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.